Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2011-08-12 Interim / Quarterly Rep…
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q2 2011
2011-08-12 English
Regulatory Filings 2011
Regulatory Filings
2011-07-28 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 30, 2011. The content focuses on the submission of matters to a vote of security holders at a special meeting, including approval of amendments to the certificate of incorporation for a reverse stock split and an amendment to the 2006 Stock Incentive Plan. The document details voting results and shareholder approvals. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is 3048 characters, which is short but contains substantive voting results, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2011-07-07 English
Capital/Financing Update 2011
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus with detailed information about the company, the offering, risk factors, management discussion, financial statements, and other disclosures typical of an IPO or public offering registration. This type of filing is related to capital raising activities and financing. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering.
2011-07-01 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 28, 2011. It announces the dismissal of a federal securities class action lawsuit against the company and its CEO. The content is primarily a regulatory disclosure of a legal event, including a press release as an exhibit. There are no financial statements, earnings data, or management discussion. The document is short (2628 characters) and serves as a regulatory announcement rather than a full report. The nature of the content relates to legal proceedings, but it is not a detailed legal report or lawsuit update filing. Given the content and format, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2011-06-28 English
M&A Activity 2011
M&A Activity Classification · 95% confidence The document is a Form 8-K/A, an amendment to a previously filed Form 8-K, filed with the SEC. It provides financial statements and pro forma financial information related to an acquisition (merger) completed by Novelos Therapeutics, Inc. The document includes audited financial statements and pro forma combined financials as exhibits. The primary purpose is to provide financial information required under Item 9.01 of Form 8-K related to the acquisition. This type of filing is a regulatory update on a merger transaction with financial disclosures, but it is not a full annual report or quarterly report. It is not a simple announcement or certification but contains substantive financial statements and pro forma data. Given the focus on acquisition-related financials and the nature of the filing, the best classification is M&A Activity (TAR).
2011-06-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.